Eva M Comperat

List of Publications by Year
in descending order

142	12,794	81889	25787
papers	citations	39 h-index	108 g-index

155	155	155	10164
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	EAU Guidelines on Nonâ€“Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. European Urology, 2017, 71, 447-461.	1.9	1,594
2	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. European Urology, 2021, 79, 82-104.	1.9	1,152
3	EAU Guidelines on Nonâ€“Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. European Urology, 2013, 64, 639-653.	1.9	1,053
4	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	1.9	936
5	EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. European Urology, 2014, 65, 778-792.	1.9	868
6	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. European Urology, 2015, 68, 868-879.	1.9	804
7	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. European Urology, 2018, 73, 111-122.	1.9	627
8	European Association of Urology Guidelines on Nonâ€“muscle-invasive Bladder Cancer (Ta, T1, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.9	559
9	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. European Urology, 2021, 79, 62-79.	1.9	532
10	EAU Guidelines on Penile Cancer: 2014 Update. European Urology, 2015, 67, 142-150.	1.9	479
11	European Association of Urology (EAU) Prognostic Factor Risk Groups for Nonâ€“muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. European Urology, 2021, 79, 480-488.	1.9	198
12	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. European Urology, 2022, 81, 95-103.	1.9	158
13	Characteristics and clinical significance of histological variants of bladder cancer. Nature Reviews Urology, 2017, 14, 651-668.	3.8	147
14	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	2.5	143
15	Eosinophilic, Solid, and Cystic Renal Cell Carcinoma. American Journal of Surgical Pathology, 2016, 40, 60-71.	3.7	139
16	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1392-1424.	5.5	138
17	EAU Guidelines on Primary Urethral Carcinoma. European Urology, 2013, 64, 823-830.	1.9	134
18	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€”An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	1.9	132

#	Article	IF	Citations
19	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Modern Pathology, 2021, 34, 1167-1184.	5.5	118
20	Predicting Response to Intravesical Bacillus Calmette-GuÃ©rin Immunotherapy: Are We There Yet? A Systematic Review. European Urology, 2018, 73, 738-748.	1.9	112
21	Grading of Urothelial Carcinoma and The New â€œWorld Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016â€• European Urology Focus, 2019, 5, 457-466.	3.1	112
22	Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 443, 115-121.	2.8	109
23	A Contemporary Update on Pathology Standards for Bladder Cancer: Transurethral Resection and Radical Cystectomy Specimens. European Urology, 2013, 63, 321-332.	1.9	103
24	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydrataseâ€“deficient Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 279-292.	3.7	101
25	What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. European Urology Oncology, 2019, 2, 625-642.	5.4	88
26	Clear Cell-Papillary Renal Cell Carcinoma of the Kidney Not Associated With End-stage Renal Disease. American Journal of Surgical Pathology, 2015, 39, 873-888.	3.7	83
27	â€œHigh-grade oncocytic renal tumorâ€• morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 725-738.	2.8	83
28	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology, 2016, 69, 441-449.	2.9	82
29	Risk Stratification Tools and Prognostic Models in Nonâ€“muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. European Urology Focus, 2020, 6, 479-489.	3.1	72
30	Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 199-205.	2.8	69
31	Reporting and Staging of Testicular Germ Cell Tumors. American Journal of Surgical Pathology, 2017, 41, e22-e32.	3.7	66
32	Accuracy of Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies to Diagnose Clinically Significant Prostate Cancer in Enlarged Compared to Smaller Prostates. Journal of Urology, 2015, 194, 669-673.	0.4	61
33	Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. European Urology, 2018, 74, 76-83.	1.9	61
34	The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. European Urology Oncology, 2020, 3, 131-144.	5.4	61
35	Prognostic Interest in Discriminating Muscularis Mucosa Invasion (T1a vs T1b) in Nonmuscle Invasive Bladder Carcinoma: French National Multicenter Study with Central Pathology Review. Journal of Urology, 2013, 189, 2069-2076.	0.4	58
36	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Nonâ€“muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Nonâ€“muscle-invasive Bladder Cancer Guidelines Panel Study. European Urology Oncology, 2021, 4, 182-191.	5.4	54

#	Article	IF	Citations
37	Genome-wide interaction study of smoking and bladder cancer risk. Carcinogenesis, 2014, 35, 1737-1744.	2.8	50
38	Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review. Neurourology and Urodynamics, 2018, 37, 1386-1395.	1.5	50
39	Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?. Cancers, 2019, 11, 422.	3.7	45
40	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. Histopathology, 2015, 67, 313-324.	2.9	41
41	NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas. Cancer Research, 2017, 77, 4835-4845.	0.9	40
42	Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. Modern Pathology, 2022, 35, 344-351.	5.5	40
43	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Nonâ€“muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. European Urology Oncology, 2021, 4, 927-942.	5.4	40
44	<scp>WHO</scp> 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology, 2022, 81, 426-438.	2.9	39
45	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Human Molecular Genetics, 2016, 25, 1203-1214.	2.9	38
46	Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. Human Pathology, 2018, 80, 55-64.	2.0	36
47	An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. Histopathology, 2013, 63, 756-766.	2.9	35
48	MRI for prostate cancer: can computed high b-value DWI replace native acquisitions?. European Radiology, 2019, 29, 5197-5204.	4.5	34
49	An introduction to the <scp>WHO</scp> 5th edition 2022 classification of testicular tumours. Histopathology, 2022, 81, 459-466.	2.9	32
50	HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 803-809.	2.8	31
51	Comprehensive integrative profiling of upper tract urothelial carcinomas. Genome Biology, 2021, 22, 7.	8.8	31
52	Effect of Genetic Variability within 8q24 on Aggressiveness Patterns at Diagnosis and Familial Status of Prostate Cancer. Clinical Cancer Research, 2008, 14, 5635-5639.	7.0	30
53	Multiparametric Magnetic Resonance Imaging Predicts Postoperative Pathology but Misses Aggressive Prostate Cancers as Assessed by Cell Cycle Progression Score. Journal of Urology, 2015, 194, 1617-1623.	0.4	30
54	European Association of Urology Guidelines on Primary Urethral Carcinomaâ€”2020 Update. European Urology Oncology, 2020, 3, 424-432.	5.4	28

#	Article	IF	Citations
55	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 440-448.	1.6	27
56	Do We Really Need to Wear Proper Eye Protection When Using Holmium:YAG Laser During Endourologic Procedures? Results from anEx VivoAnimal Model on Pig Eyes. Journal of Endourology, 2016, 30, 332-337.	2.1	26
57	Ductal adenocarcinoma of the prostate: Clinical and biological profiles. Prostate, 2017, 77, 1242-1250.	2.3	26
58	En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. Journal of Urology, 2022, 207, 754-768.	0.4	26
59	The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease. Cancer Research, 2014, 74, 5808-5818.	0.9	24
60	VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments. Ultrasound in Medicine and Biology, 2015, 41, 2202-2211.	1.5	23
61	Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results. Hormones and Cancer, 2019, 10, 36-44.	4.9	23
62	Prostate cancer local staging using biparametric MRI: assessment and comparison with multiparametric MRI. European Journal of Radiology, 2020, 132, 109350.	2.6	23
63	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Advances in Anatomic Pathology, 2021, 28, 179-195.	4.3	23
64	Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed?. European Radiology, 2018, 28, 3760-3769.	4.5	22
65	Dynamic contrastâ€enhanced imaging in localizing local recurrence of prostate cancer after radiotherapy: Limited added value for readers of varying level of experience. Journal of Magnetic Resonance Imaging, 2018, 48, 1012-1023.	3.4	21
66	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Scientific Reports, 2020, 10, 701.	3.3	21
67	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Advances in Anatomic Pathology, 2021, 28, 196-208.	4.3	20
68	Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours. World Journal of Urology, 2013, 31, 53-59.	2.2	19
69	Reactivity of <scp>CK</scp>7 across the spectrum of renal cell carcinomas with clear cells. Histopathology, 2019, 74, 608-617.	2.9	18
70	Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. World Journal of Urology, 2021, 39, 4355-4361.	2.2	18
71	Similarities and Differences in the 2019 ISUP and GUPS Recommendations on Prostate Cancer Grading: A Guide for Practicing Pathologists. Advances in Anatomic Pathology, 2021, 28, 1-7.	4.3	18
72	Twoâ€photon optical imaging, spectral and fluorescence lifetime analysis to discriminate urothelial carcinoma grades. Journal of Biophotonics, 2018, 11, e201800065.	2.3	17

#	Article	IF	Citations
73	A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 637-645.	2.8	17
74	Intraoperative Consultation and Macroscopic Handling. American Journal of Surgical Pathology, 2018, 42, e33-e43.	3.7	16
75	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. European Urology, 2019, 76, 179-186.	1.9	15
76	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2022, 82, 82-96.	1.9	15
77	Immunochemical and molecular assessment of urothelial neoplasms and aspects of the 2016 World Health Organization classification. Histopathology, 2016, 69, 717-726.	2.9	14
78	Relationship between non-suspicious MRI and insignificant prostate cancer: results from a monocentric study. World Journal of Urology, 2016, 34, 673-678.	2.2	14
79	InÂVivo Multiparametric Ultrasound Imaging of Structural and Functional Tumor Modifications during Therapy. Ultrasound in Medicine and Biology, 2017, 43, 2000-2012.	1.5	14
80	HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 133-136.	2.8	12
81	Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound. European Urology, 2022, 82, 261-270.	1.9	11
82	Pathomics in urology. Current Opinion in Urology, 2020, 30, 823-831.	1.8	10
83	Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study. Advances in Anatomic Pathology, 2020, 27, 303-310.	4.3	10
84	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. European Urology Focus, 2022, 8, 761-768.	3.1	10
85	Comprehensive study of nine novel cases of <scp>TFEB</scp>â€amplified renal cell carcinoma: an aggressive tumour with frequent <scp>PDL1</scp> expression. Histopathology, 2022, 81, 228-238.	2.9	10
86	<scp>WHO</scp> Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology, 2022, 81, 447-458.	2.9	10
87	Atlas of Ex Vivo Prostate Tissue and Cancer Images Using Confocal Laser Endomicroscopy: A Project for Intraoperative Positive Surgical Margin Detection During Radical Prostatectomy. European Urology Focus, 2020, 6, 941-958.	3.1	9
88	The Genetic Complexity of Prostate Cancer. Genes, 2020, 11, 1396.	2.4	9
89	What Does COVID-19 Mean for the Pathology-Urology Interaction?. European Urology, 2020, 78, e43-e44.	1.9	9
90	Analysis of bladder cancer subtypes in neurogenic bladder tumors. Canadian Journal of Urology, 2018, 25, 9161-9167.	0.0	9

#	Article	IF	Citations
91	Indication for a Single Postoperative Instillation of Chemotherapy in Nonâ€“muscle-invasive Bladder Cancer: What Factors Should Be Considered?. European Urology Focus, 2018, 4, 525-528.	3.1	8
92	SIUâ€“ICUD on bladder cancer: pathology. World Journal of Urology, 2019, 37, 41-50.	2.2	8
93	Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis. Cancers, 2021, 13, 2496.	3.7	8
94	Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies. World Journal of Urology, 2022, 40, 915-927.	2.2	8
95	Squamous Cell Carcinoma of the Bladder Is Not Associated With High-risk HPV. Urology, 2020, 144, 158-163.	1.0	7
96	Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. European Journal of Surgical Oncology, 2021, 47, 1172-1178.	1.0	7
97	Comparative Outcomes of Primary Versus Recurrent High-risk Nonâ€“muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. European Urology Open Science, 2022, 39, 14-21.	0.4	7
98	Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 605-613.	2.8	6
99	Papillary Renal Cell Carcinoma: A Family Portrait. European Urology, 2018, 73, 79-80.	1.9	6
100	Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol 2019;76:413â€“5. European Urology, 2019, 76, 416-417.	1.9	6
101	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 295.e1-295.e8.	1.6	6
102	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Molecular Carcinogenesis, 2022, 61, 5-18.	2.7	6
103	Bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis: are they the same tumors?. World Journal of Urology, 2022, 40, 1949-1959.	2.2	6
104	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. Annals of Surgical Oncology, 2022, 29, 5307-5316.	1.5	6
105	Classification of Adult Renal Tumors: An Update. Seminars in Ultrasound, CT and MRI, 2017, 38, 2-9.	1.5	5
106	Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureterâ€”Nephroureterectomy and Ureterectomy Specimens. American Journal of Surgical Pathology, 2019, 43, e1-e12.	3.7	5
107	Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. American Journal of Pathology, 2020, 190, 442-452.	3.8	5
108	Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study. Journal of Clinical Medicine, 2021, 10, 764.	2.4	5

#	Article	IF	Citations
109	Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review. Current Opinion in Urology, 2021, 31, 324-331.	1.8	5
110	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. Journal of Urology, 2021, 206, 1122-1131.	0.4	5
111	Renal Pseudo-tumor Related to Renal Splenosis: Imaging Features. Urology, 2018, 114, e11-e15.	1.0	4
112	Changes of Tumourâ€“Nodeâ€“Metastasis Staging in 2017: Concepts and Evolutions in the European and American Continents. European Urology, 2018, 73, 570-571.	1.9	4
113	A systematic review and meta-analysis of prognostic impact of different Gleason patterns in ISUP grade group 4. Minerva Urology and Nephrology, 2021, 73, 42-49.	2.5	4
114	Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer. European Urology Open Science, 2021, 30, 63-66.	0.4	4
115	Transurethral resection of bladder and radical cystectomy: Concordance of histology. Are we good enough?. Turkish Journal of Urology, 2020, 46, 354-359.	1.3	4
116	Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma. , 2010, 32, 39-44.		4
117	Flat intraurothelial lesions of the urinary bladderâ€”do hyperplasia, dysplasia, and atypia of unknown significance need to exist as diagnostic entities? and how to handle in routine clinical practice. Modern Pathology, 2022, 35, 1296-1305.	5.5	4
118	Dynamic evaluation of MRI-targeted, systematic and combined biopsy for prostate cancer diagnosis through 10Âyears of practice in a single institution. World Journal of Urology, 2022, 40, 1661-1668.	2.2	4
119	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Nonâ€“muscle-invasive Bladder Cancer Spectrum. European Urology Focus, 2022, , .	3.1	4
120	Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 2019, 75, 453-467.	2.9	3
121	Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. Annals of Surgical Oncology, 2021, 28, 9179-9187.	1.5	3
122	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. European Urology Focus, 2022, 8, 972-979.	3.1	3
123	Brief update of the new WHO classification for urothelial carcinoma. Current Opinion in Urology, 0, Publish Ahead of Print, .	1.8	3
124	Pathological and molecular aspects of urothelial carcinomas. Diagnostic Histopathology, 2020, 26, 330-336.	0.4	2
125	Genetic variability in 13q33 and 9q34 is linked to aggressiveness patterns and a higher risk of progression of nonâ€muscleâ€invasive bladder cancer at the time of diagnosis. BJU International, 2021, 127, 375-383.	2.5	2
126	Pathological reporting of cystectomy lymph nodes: a retrospective analysis of experience in Paris. World Journal of Urology, 2021, 39, 4029-4035.	2.2	2

#	Article	IF	Citations
127	More than ancillary records: clinical implications of renal pathology examination in tumor nephrectomy specimens. Journal of Nephrology, 2021, 34, 1833-1844.	2.0	2
128	PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers. World Journal of Urology, 2021, 39, 4067-4071.	2.2	2
129	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3091-3102.	2.5	2
130	A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology. World Journal of Urology, 2022, , 1.	2.2	2
131	Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations. Journal of Personalized Medicine, 2021, 11, 1147.	2.5	1
132	Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer. Biomarkers in Medicine, 2022, 16, 449-459.	1.4	1
133	Re: Analysis of Papillary Urothelial Carcinomas of the Bladder with Grade Heterogeneity: Supportive Evidence for an Early Role of CDKN2A Deletions in the FGFR3 Pathway. European Urology, 2017, 71, 690.	1.9	0
134	Therapeutic rationale of targeting BCG and immune checkpoints in nonâ€“muscle-invasive bladder cancer: Is this the Future?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 343-345.	1.6	0
135	Evolution of prostate cancer histopathology. Current Opinion in Urology, 2019, 29, 587-592.	1.8	0
136	Re: Greater Utility of Molecular Subtype Rather than Epithelial-to-mesenchymal Transition (EMT) Markers for Prognosis in High-risk Non-muscle-invasive (HGT1) Bladder Cancer. European Urology, 2020, 78, 764.	1.9	0
137	Diagnosis of prostate cancer in one day: The benefits of cytology in tumour detection. Cytopathology, 2021, 32, 211-216.	0.7	0
138	Editorial for Cribriform architecture prostatic adenocarcinoma in needle biopsy is a strong independent predictor for lymph node metastases in radical prostatectomy (M. DownesÂetÂal.) and Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival (K. Chow etÂal.). European Journal of Cancer, 2021, 148, 430-431.	2.8	0
139	Single-lesion PSMA protein expression and response to Lu-177 PSMA therapy in patients with castration-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 5065-5065.	1.6	0
140	Latest Developments and Current Problems in Bladder Cancer. World Journal of Urology, 2021, 39, 4009-4010.	2.2	0
141	ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?. Annals of Surgical Oncology, 2022, , 1.	1.5	0
142	ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. Annals of Surgical Oncology, 2022, , 1.	1.5	0